Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets
Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades
Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like
Texas Life Science Forum: Reglagene is aiming to get tubulin therapies across the blood brain barrier so they can treat brain cancers
Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year
Texas Life Science Forum: NKILT Therapeutics is emerging into the in-vivo proof of concept stage of testing its HLA-G targeting cell therapy
BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24
BIO-Europe: Centauri Therapeutics is planning to use antibody recruiting sugars that are linked to a targeting agent to treat infectious disease and cancer
BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology
BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year
BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting
BIO-Europe: The CEO of Sweden's Affibody on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors
BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform
.png){kind=logo}
